HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Thematic (Sector/Industry)

<ul>
<li>SVB has special institutions in China and its business mode is Venture Lending. The closure of SVB could make it harder for Chinese startups to raise money from US investors/banks.</li>
<li>The scale of SVB is small, but it cannot be said that it has no impact on the fundamentals of China healthcare companies. Investors need to reassess the potential risks.</li>
<li>SVB’s woes would not be a serious blow to the US if government takes timely action. However, if BRICS currency is established, it would be real fatal for the dollar.</li>
</ul>


SVB has special institutions in China and its business mode is Venture Lending. The closure of SVB could make it harder for Chinese startups to raise money from US investors/banks.
The scale of SVB is small, but it cannot be said that it has no impact on the fundamentals of China healthcare companies. Investors need to reassess the potential risks.
SVB’s woes would not be a serious blow to the US if government takes timely action. However, if BRICS currency is established, it would be real fatal for the dollar.


“Sudden Death” of Silicon Valley Bank (SVB) - The Impact on China Healthcare

China/Asia TMT

Shawn Yang

China growth and global non-US Internet equities

Blue Lotus Research Institute

Blue Lotus Research is a Hong Kong Type 4 Licensed investment advisory firm focusing on Chinese growth equities and global non-US Internet equities

<ul>
<li>9926HK：Summit Therapeutics completed US$500mn rights offering to pay for Akeso's AK112 (+)</li>
<li>3690HK：Meituan closure of self-operated taxi business may have 6% benefit to net profit in 2023 (+)</li>
<li>ZLAB：HBM announced Phase III success of FcRn drug treating MG, about to compete against ZLAB's Efgartigimod(-)</li>
</ul>


9926HK：Summit Therapeutics completed US$500mn rights offering to pay for Akeso's AK112 (+)
3690HK：Meituan closure of self-operated taxi business may have 6% benefit to net profit in 2023 (+)
ZLAB：HBM announced Phase III success of FcRn drug treating MG, about to compete against ZLAB's Efgartigimod(-)


China TMT Update(Mar.8): 9926HK,ZLAB,3690HK: Meituan Closure of Self-Operated Taxi Business (+)

Equity Bottom-Up

<ul>
<li>ZaiLab reported C4Q22 top line 3% above our estimate. Operating profit was worse than our estimate and consensus while net income was better mainly due to government grant; </li>
<li>We maintain ZLAB’s business model is inherently flawed because each blockbuster drug it signed needs comprehensive sales support.</li>
<li>As a result, ZLAB’s pipeline needs to be heavily discounted; We maintain our SELL and cut TP from US$30 to US$25.</li>
</ul>


ZaiLab reported C4Q22 top line 3% above our estimate. Operating profit was worse than our estimate and consensus while net income was better mainly due to government grant; 
We maintain ZLAB’s business model is inherently flawed because each blockbuster drug it signed needs comprehensive sales support.
As a result, ZLAB’s pipeline needs to be heavily discounted; We maintain our SELL and cut TP from US$30 to US$25.


[Zai LAB (ZLAB US) Earnings Review]: Pretty Much the Same…Maintain SELL

<ul>
<li>ZLAB: Merck's Keytruda received repeated setbacks on treating prostate cancer, but the result cannot benefit ZLAB(/)</li>
<li>9995HK: RemeGen preannounced 2022 results, which is slightly better than our estimate</li>
<li>1877HK: JUNSHI preannounced 2022 result, which was worse than we expected</li>
</ul>


ZLAB: Merck's Keytruda received repeated setbacks on treating prostate cancer, but the result cannot benefit ZLAB(/)
9995HK: RemeGen preannounced 2022 results, which is slightly better than our estimate
1877HK: JUNSHI preannounced 2022 result, which was worse than we expected


China TME Update (Mar.2) - ZLAB; 9995HK;1877HK

<ul>
<li>ZaiLab and NovoCure (NVCR US, NR) surged on positive readout of Optune’s Phase III on Non-Small-Cell-Lung Cancer (NSCLC), a major indication win after the smaller ones in Glioblastoma and Mesothelioma.</li>
<li>We, however, caution that the readout is largely expected and Optune faces uncertainty in commercialization both globally and in China;</li>
<li>We raise TP to US$35 to reflect possible readouts in other cancer types</li>
</ul>


ZaiLab and NovoCure (NVCR US, NR) surged on positive readout of Optune’s Phase III on Non-Small-Cell-Lung Cancer (NSCLC), a major indication win after the smaller ones in Glioblastoma and Mesothelioma.
We, however, caution that the readout is largely expected and Optune faces uncertainty in commercialization both globally and in China;
We raise TP to US$35 to reflect possible readouts in other cancer types


Zai LAB (ZLAB.US/9688.HK)：TTF Is Not a Done Deal, Both China and Globally

China

Zai Lab Limited operates as a bio-pharmaceutical company. The Company researches and develops therapeutic technology for antibody-based oncology, autoimmune, and infectious diseases treatments. Zai Lab also manufactures drugs in the form of capsules, injections, and liquids. Zai Lab serves patients worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Zai Lab Ltd (ZLAB US)

“Sudden Death” of Silicon Valley Bank (SVB) - The Impact on China Healthcare

SVB's "sudden death" would affect Chinese healthcare companies. Investors need to reassess the risks of related companies.We don't think SVB’s woes...

Xinyao (Criss) Wang

China TMT Update(Mar.8): 9926HK,ZLAB,3690HK: Meituan Closure of Self-Operated Taxi Business (+)

ZLAB：HBM announced Phase III success of FcRn drug treating MG(-) 3690HK：Meituan closure of self-operated taxi business may have 6% benefit to net...

Blue Lotus Research Institute

[Zai LAB (ZLAB US) Earnings Review]: Pretty Much the Same…Maintain SELL

We maintain ZLAB’s business model is inherently flawed because each blockbuster drug it signed needs comprehensive sales support. As a result,...

Blue Lotus Research Institute

China TME Update (Mar.2) - ZLAB; 9995HK;1877HK

ZLAB: Merck's Keytruda received repeated setbacks on treating prostate cancer, but the result cannot benefit ZLAB(/); 9995HK: RemeGen preannounced...

Blue Lotus Research Institute

Zai LAB (ZLAB.US/9688.HK)：TTF Is Not a Done Deal, Both China and Globally

ZaiLab and NovoCure surged on positive readout of Optune’s Phase III on Non-Small-Cell-Lung Cancer (NSCLC). We, however, caution that Optune faces...

Blue Lotus Research Institute

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)